Andrei‐Mircea Catarig
About
Andrei‐Mircea Catarig is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery.
According to data from OpenAlex, Andrei‐Mircea Catarig has authored 30 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Endocrinology, Diabetes and Metabolism, 22 papers in Molecular Biology and 7 papers in Surgery. Recurrent topics in Andrei‐Mircea Catarig's work include Diabetes Treatment and Management (27 papers), Metabolism, Diabetes, and Cancer (22 papers) and Diabetes Management and Research (16 papers). Andrei‐Mircea Catarig is often cited by papers focused on Diabetes Treatment and Management (27 papers), Metabolism, Diabetes, and Cancer (22 papers) and Diabetes Management and Research (16 papers). Andrei‐Mircea Catarig collaborates with scholars based in Denmark, United States and United Kingdom. Andrei‐Mircea Catarig's co-authors include Ildiko Lingvay, Matthew Capehorn, Desirée Thielke, Nanna L. Lausvig, Rory J. McCrimmon, Juan P. Frías, Carel W. le Roux, Andrej Janež, Hermione Price and Bruno Vergès and has published in prestigious journals such as The Lancet, Journal of the American College of Cardiology and The Journal of Clinical Endocrinology & Metabolism.
In The Last Decade
Andrei‐Mircea Catarig
29 papers receiving 997 citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Andrei‐Mircea Catarig Denmark | 17 | 899 | 623 | 241 | 171 | 115 | 30 | 1.0k | ||
| Julie Derving Karsbøl Denmark | 9 | 1.1k 1.2× | 737 1.2× | 290 1.2× | 277 1.6× | 94 0.8× | 15 | 1.2k | ||
| Zin Zin Htike United Kingdom | 10 | 804 0.9× | 365 0.6× | 180 0.7× | 283 1.7× | 103 0.9× | 14 | 924 | ||
| P. Miossec France | 12 | 991 1.1× | 455 0.7× | 204 0.8× | 376 2.2× | 83 0.7× | 22 | 1.1k | ||
| Katja Rohwedder Germany | 12 | 1.2k 1.4× | 698 1.1× | 275 1.1× | 577 3.4× | 62 0.5× | 35 | 1.3k | ||
| Shizuka Kaneko Japan | 11 | 847 0.9× | 400 0.6× | 287 1.2× | 291 1.7× | 188 1.6× | 23 | 1.0k | ||
| Michaël J.B. van Baar Netherlands | 7 | 656 0.7× | 233 0.4× | 108 0.4× | 311 1.8× | 53 0.5× | 12 | 773 | ||
| S. Durán‐García Spain | 11 | 978 1.1× | 497 0.8× | 189 0.8× | 441 2.6× | 45 0.4× | 20 | 1.1k | ||
| Nobuko Maruyama Japan | 12 | 566 0.6× | 254 0.4× | 77 0.3× | 321 1.9× | 56 0.5× | 14 | 618 | ||
| Trine Saugstrup Denmark | 6 | 405 0.5× | 284 0.5× | 124 0.5× | 98 0.6× | 54 0.5× | 8 | 611 | ||
| Ludwig Merker Germany | 10 | 1.3k 1.5× | 525 0.8× | 193 0.8× | 719 4.2× | 70 0.6× | 30 | 1.4k |
Countries citing papers authored by Andrei‐Mircea Catarig
Since
Specialization
Citations
This map shows the geographic impact of Andrei‐Mircea Catarig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrei‐Mircea Catarig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrei‐Mircea Catarig more than expected).
Fields of papers citing papers by Andrei‐Mircea Catarig
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Andrei‐Mircea Catarig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrei‐Mircea Catarig. The network helps show where Andrei‐Mircea Catarig may publish in the future.
Co-authorship network of co-authors of Andrei‐Mircea Catarig
This figure shows the co-authorship network connecting the top 25 collaborators of Andrei‐Mircea Catarig. A scholar is included among the top collaborators of Andrei‐Mircea Catarig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrei‐Mircea Catarig. Andrei‐Mircea Catarig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Bonaca, Marc P., Andrei‐Mircea Catarig, Kim Christian Houlind, et al.. (2025). Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. The Lancet. 405(10489). 1580–1593.
2.
Yale, Jean‐François, et al.. (2024). Real‐world safety profile of once‐weekly semaglutide in people with type 2 diabetes: Analysis of pooled data from the SemaglUtide Real‐world Evidence (SURE) programme. Diabetes Obesity and Metabolism. 26(10). 4429–4440.
3.
Lassen, Mats Christian Højbjerg, Niklas Dyrby Johansen, Daniel Modin, et al.. (2024). Adherence to glucagon‐like peptide ‐1 receptor agonist treatment in type 2 diabetes mellitus: A nationwide registry study. Diabetes Obesity and Metabolism. 26(11). 5239–5250.
4.
Lassen, Mats Christian Højbjerg, Niklas Dyrby Johansen, Daniel Modin, et al.. (2024). Persistence and Adherence to GLP-1 RA treatment in Type 2 Diabetes Mellitus: a Nationwide registry study. European Heart Journal. 45(Supplement_1).
5.
Rudofsky, Gottfried, et al.. (2024). Glucagon-Like Peptide-1 Receptor Agonist-Experienced Adults with Type 2 Diabetes Switching to Once-Weekly Semaglutide in a Real-World Setting: SURE Program Post Hoc Analysis. Advances in Therapy. 42(2). 788–800.
6.
Hach, Morten, Kim F. Haselmann, Kasper Lamberth, et al.. (2024). Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs. Pharmaceutical Research. 41(10). 1991–2014.
7.
Bonaca, Marc P., Andrei‐Mircea Catarig, Kim Christian Houlind, et al.. (2024). Design and baseline characteristics of the STRIDE trial: evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetes. European Heart Journal - Cardiovascular Pharmacotherapy. 10(8). 728–737.
8.
Mohammedi, Kamel, et al.. (2023). Once‐weekly semaglutide use in patients with type 2 diabetes: Results from the SURE France multicentre, prospective, observational study. Diabetes Obesity and Metabolism. 25(7). 1855–1864.
9.
Napoli, Raffaele, Cesare Berra, Andrei‐Mircea Catarig, et al.. (2023). Once‐weekly semaglutide use in patients with type 2 diabetes: Real‐world data from the SURE Italy observational study. Diabetes Obesity and Metabolism. 25(6). 1658–1667.
10.
Berentzen, Tina Landsvig, et al.. (2023). Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany. Experimental and Clinical Endocrinology & Diabetes. 131(4). 205–215.
11.
Bellido, Virginia, et al.. (2022). Once-Weekly Semaglutide Use in Patients with Type 2 Diabetes: Results from the SURE Spain Multicentre, Prospective, Observational Study. Journal of Clinical Medicine. 11(17). 4938–4938.
12.
Lingvay, Ildiko, Andrei‐Mircea Catarig, Jack Lawson, et al.. (2022). An Indirect Comparison of Basal Insulin Plus Once-Weekly Semaglutide and Fully Optimised Basal–Bolus Insulin in Type 2 Diabetes. Diabetes Therapy. 14(1). 123–137.
13.
Wolffenbuttel, Bruce H. R., et al.. (2022). Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study. Advances in Therapy. 40(3). 920–933.
14.
Pratley, Richard E., Andrei‐Mircea Catarig, Ildiko Lingvay, et al.. (2021). An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg. Diabetes Obesity and Metabolism. 23(11). 2513–2520.
15.
Catarig, Andrei‐Mircea, et al.. (2021). Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from the SURE UK Multicentre, Prospective, Observational Study. Diabetes Therapy. 12(11). 2891–2905.
16.
Ekberg, Neda Rajamand, et al.. (2021). Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study. Primary care diabetes. 15(5). 871–878.
17.
Rudofsky, Gottfried, Andrei‐Mircea Catarig, Lucie Favre, et al.. (2021). Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Switzerland multicentre, prospective, observational study. Diabetes Research and Clinical Practice. 178. 108931–108931.
18.
McCrimmon, Rory J., Andrei‐Mircea Catarig, Juan P. Frías, et al.. (2020). Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia. 63(3). 473–485.
19.
Pratley, Richard E., Vanita R. Aroda, Andrei‐Mircea Catarig, et al.. (2020). Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses. BMJ Open. 10(11). e037883–e037883.
20.
Capehorn, Matthew, Andrei‐Mircea Catarig, Andrej Janež, et al.. (2019). Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes & Metabolism. 46(2). 100–109.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Julie Derving Karsbøl Breakdown of academic impact, for papers by Zin Zin Htike Breakdown of academic impact, for papers by P. Miossec Breakdown of academic impact, for papers by Katja Rohwedder Breakdown of academic impact, for papers by Shizuka Kaneko Breakdown of academic impact, for papers by Michaël J.B. van Baar Breakdown of academic impact, for papers by S. Durán‐García Breakdown of academic impact, for papers by Nobuko Maruyama Breakdown of academic impact, for papers by Trine Saugstrup Breakdown of academic impact, for papers by Ludwig Merker